Search
forLearn
5 / 801 resultslearn capilia longa
learn lodine
learn Pea peptides
learn Keracyn
Research
5 / 1000+ results
research Sericin hydrogels promote skin wound healing with effective regeneration of hair follicles and sebaceous glands after complete loss of epidermis and dermis
Sericin hydrogels heal skin wounds well, regrowing hair and glands with less scarring.
research Commentary: Hair Transplantation for Reconstruction of Scalp Defects using Artificial Dermis
Artificial dermis used for hair transplantation can reconstruct scalp defects effectively without the need for tissue expansion.
research Transcriptomic analyses of regenerating adult feathers in chicken
Chicken feather growth involves specific genes and shares similarities with hair development.
research Effectiveness and safety of baricitinib in severe alopecia areata: 48-week results
Baricitinib effectively promotes hair regrowth and improves well-being in severe alopecia areata patients.
research COVID‐19 and dermatology: a comprehensive guide for dermatologists
Dermatologists should watch for skin symptoms in COVID-19 patients, prioritize urgent cases, and use telemedicine.
Community Join
5 / 1000+ resultscommunity Pelage Recruiting Now for Phase 2
Pelage is recruiting for phase 2 trials, showing promise for treating bald regions. The discussion highlights its potential effectiveness based on its mechanism of action.
community $120 million Series B funding to Pelsge
Pelage Pharmaceuticals received $120 million in Series B funding for hair loss treatment development. The conversation expresses excitement and anticipation for the release and effectiveness of the treatment.
community Pelage Pharmaceutical Raises 120 million to continue PP405 Research. Link inside.
Pelage Pharmaceutical raised $120 million to continue research on PP405, a promising hair loss treatment that showed a 20% increase in hair density in 31% of men during a Phase 2a trial. The treatment was well-tolerated, with no systemic absorption, and Phase 3 trials are planned for 2026.
community Pelage Pharmaceuticals’ PP405 and its Impact on Follicular Regeneration to be Presented at the American Academy of Dermatology (AAD) Annual Meeting 2026 28th march
Pelage Pharmaceuticals' PP405 aims to treat hair loss by reactivating dormant hair follicle stem cells, showing promising results in early trials. The company plans to present their findings at the American Academy of Dermatology Annual Meeting in 2026.
community Quote from Pelage (PP-405) Spokesperson...
Pelage is developing a topical hair follicle stem cell therapy, PP405, for non-scarring alopecias like androgenetic alopecia, with Phase III trials planned and a potential market launch by 2027. The treatment may not require continuous use after initial regrowth.